-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US00439U1043 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 1.37 |
|---|---|
| Market Cap | 35M |
| PE Ratio | None |
| Target Price | 11.6496 |
| Dividend Yield | None |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GRCE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025